CNIPA.AI
Patent applicant records

APPLICANTS

Original name record: UT-Heart Inc.

Browse source applicant names and unchanged name fields from imported patent records.

These are name-based results, not verified legal entities. Identical names may refer to different people or organizations; aliases and historical names are not merged.

This page matches the complete original name field. It may contain multiple applicants or another recorded party role. Name boundaries and legal identities have not been verified; punctuation is preserved, not split.

1 indexed patent records

Patent counts refer to distinct records held by this site, not an applicant’s complete portfolio. A joint name field is not a single company.

Verified corpus date coverage and last import time are not currently available. Publication dates on patent records are not import dates. Cached directory results may lag behind new imports.

Search the local original applicant field containing this full text. Results may include joint lists or longer names; this is not an exact identity search.

Search patents with this applicant condition
№ US20260004938A1Invention
Pending

IN-SILICO CARDIAC DISEASE DATABASE UTILIZATION METHOD, IN-SILICO CARDIAC DISEASE DATABASE UTILIZATION PROGRAM AND INFORMATION PROCESSING DEVICE

IN-SILICO CARDIAC DISEASE DATABASE UTILIZATION METHOD, IN-SILICO CARDIAC DISEASE DATABASE UTILIZATION PROGRAM AND INFORMATION PROCESSING DEVICE

An information processing technology capable of increasing prediction accuracy of causing cardiac diseases, performing appropriate therapy and increasing efficiency of drug development is constructed by utilizing “in-silico cardiac disease database.” An electrocardiogram and the like obtained from “in-silico cardiac disease database” which is the database storing a simulation result of a cardiac model of virtual disease where various factor related to cardiac disease are changed are inputted to a classifier for performing an automatic diagnosis of the cardiac disease, and an influencing factor associated with the cardiac disease is identified as a biomarker by comparing distributions of a variation amount of a factor between a positive group and a negative group. In addition, precise diagnosis of an individual is easily performed by identifying the cardiac model having the electrocardiogram and the like appropriate to the actual electrocardiogram and the like of the individual in the in-silico cardiac disease database. Furthermore, the process of drug development is efficiently performed by extracting a group having a predetermined feature from the in-silico cardiac disease database and simply evaluating an effect of an administration of a medical agent.

❖UT-Heart Inc.Toshiaki HISADA; Seiryo SUGIURA; Takumi WASHIO; Jun-ichi OKADA; Katsuhito FUJIU§ 3/10 ClaimsG16H 50/70, A61B 8/, A61B 8/8 +111